MERK Merck Tbk


Saham MERK Merck Tbk - Berita, Prospek, dan Analisa - :
Stocks Asia - Berita saham, analisis saham, dan prospek saham
Tip: Gunakan untuk menyimpan saham-saham favorit
MERK Merck Tops Analyst Estimates on Strong Keytruda, Gardasil, and Bridion Sales By Investing.com
29 Jul 2022 01:04 (1 bulan 28 hari lalu) - By Sam Boughedda Merck's (NYSE: MRK) shares dipped in the early part of Thursday's session after it reported second-quarter earnings. Profit and revenue topped analyst expectations, but the company's shares fell as low as $87.42 after guidance disappointed investors. The stock has since regained the majority of its initial losses. Merck posted earnings of $1.87, $0.19 better than the analyst estimate of $1.68, with revenue coming in at $14.6 billion versus the consensus estimate of $13.83 billion, a 28% increase compared to the same period last year. "Our strategy is working and our future is bright. I am very confident that we are well-p ...
MERK Merck quarterly profit tops Wall Street view on strong Keytruda sales By Reuters
28 Jul 2022 17:32 (1 bulan 28 hari lalu) - By Michael Erman (Reuters) - Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer drug Keytruda. The company said it earned $4.74 billion in the quarter, or $1.87 a share, compared with $1.55 billion, or 61 cents a share, a year earlier. Analysts on average had expected the company to earn $1.70 a share, according to Refinitiv data. Revenue in the quarter rose 28% from a year ago to $14.6 billion, topping the average Wall Street forecast of $13.9 billion. Much of that beat came from sales of Merck's top-selling drug, the cancer immunotherapy Keytruda, which came ...
MERK Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator By Reuters
27 Jul 2022 21:07 (1 bulan 29 hari lalu) - By Michael Erman (Reuters) - Drugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, according to an ongoing investigation by Democrats on the Senate Finance Committee. The committee's chairman Senator Ron Wyden of Oregon sent a letter to Merck Chief Executive Robert Davis on Wednesday criticizing the drugmaker for refusing to provide all the information the committee has requested. Wyden's office provided a copy of the letter to Reuters. Democrats on the committee have been investigating how the tax la ...
MERK Netflix, Omnicom Rise Premarket; Baker Hughes, Merck Fall By Investing.com
20 Jul 2022 19:00 (2 bulan 6 hari lalu) - By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Wednesday, July 20th. Please refresh for updates. - Netflix (NASDAQ: NFLX) stock rose 6.6% after the streaming giant soothed concerns by predicting it will return to customer growth during the third quarter, averting its own worst-case scenario of subscriber losses, posting a nearly 1 million drop from April through June. - Twitter (NYSE: TWTR) stock fell 0.2% after a judge ordered that the five-day trial between Elon Musk and the social media platform will take place in October and not next year as requested by the billionaire CEO. - Chevron (NYSE: CVX) stock fell 0.3%, ...
MERK Merck's Keytruda fails head and neck cancer trial By Reuters
20 Jul 2022 18:09 (2 bulan 6 hari lalu) - (Reuters) - Merck & Co Inc said on Wednesday its cancer therapy Keytruda failed to meet the main goal of a late-stage trial testing it in patients with head and neck cancer. The company said Keytruda, its blockbuster cancer drug, in combination with chemoraditation therapy showed improvement in event-free survival, or the period of time a patient remains free of complications compared to a placebo. However, the results did not meet statistical significance. Keytruda showed a safety profile similar to previously reported studies, according to Merck. The drug belongs to a class of treatments called PD-1 inhibitors, which work by boosting th ...
MERK Merck Merck's Seagen Deal to be Delayed Says WSJ By Investing.com
18 Jul 2022 21:05 (2 bulan 8 hari lalu) - By Sam Boughedda According to the Wall Street Journal, Merck's (NYSE: MRK) approximately $40 million deal to acquire Seagen (NASDAQ: SGEN) is "unlikely to be finalized" before Merck's second quarter earnings release on July 28. Following the news, Seagen shares have tumbled over 4%, while Merck shares are down 0.5%. The WSJ, citing sources familiar with the matter, said talks remain on track but have been delayed. Earlier this month, they reported that Merck planned to acquire Seagen within a few weeks. The delay and change in schedule are said to be due to the company needing to wait for data from a Seagen treatment study evaluating Seag ...
MERK Finnish Pharma Firm Orion Raises Outlook After Merck Agreement By Investing.com
13 Jul 2022 17:47 (2 bulan 13 hari lalu) - By Scott Kanowsky Investing.com -- Shares in Orion (HE: ORNBV) rose on Wednesday after the Finnish pharmaceutical company upgraded its annual outlook following a cancer drug manufacturing agreement with U.S. peer Merck & Company (NYSE: MRK). In a statement, Orion said it now expects full-year operating profit and net sales to be "clearly higher" than in 2021. It previously said the results would be at similar levels to the prior year. The raised guidance partly stems from an upfront payment of $290 million that Orion will receive under the terms of the deal, the firm added. Orion will work with a subsidiary of Merck & Co that runs the dru ...
MERK Orion raises outlook after Merck deal on developing prostate cancer drug By Reuters
13 Jul 2022 13:35 (2 bulan 13 hari lalu) - (Reuters) -Finnish drug maker Orion on Wednesday raised its full year outlook after it signed a collaboration agreement with Merck aimed at developing a prostate cancer drug, sending its shares to two-year high. Given the upfront payment of $290 million Orion is to receive from Merck, the Finnish company expects sales and operating profit in 2022 to be "clearly higher" than in 2021. "This agreement positions Orion to harness the potential of ODM-208 for the good of patients while continuing to invest in our other programs without compromising our financial targets", Orion's Chief Executive Timo Lappalainen said in a statement. The deal for ...
MERK Labor Market Data, Johnson Quits, China Stimulus Plan - What's Moving Markets By Investing.com
07 Jul 2022 17:26 (2 bulan 19 hari lalu) - By Geoffrey Smith Investing.com -- Jobless claims and the Challenger Job Cuts report will give the market more to chew on before Friday's all-important jobs report, and there are a couple of Federal Reserve speakers to help people interpret them. China is planning a big stimulus program in the second half of the year. Merck is on the verge of buying cancer specialist Seagen for $40 billion, according to report. Shell signals that high oil and gas prices are back for the foreseeable future, and U.K. Prime Minister Boris Johnson finally throws in the towel. Here's what you need to know in financial markets on Thursday, 7th July. 1. Labor mark ...
MERK Merck in Advanced Talks to Acquire Seagen for $40 Billion - WSJ By Investing.com
07 Jul 2022 16:39 (2 bulan 19 hari lalu) - By Senad Karaahmetovic Merck & Co. (NYSE: MRK) is close to agreeing to buy the biotechnology company Seagen (NASDAQ: SGEN) in a deal that can be worth about $40 billion, according to a report in the Wall Street Journal. The ongoing talks suggest that Merck could pay more than $200 per share to acquire Seagen and the two companies are looking to close the deal prior to Merck’s quarterly earnings report, scheduled for July 28. Shares of Seagen are up nearly 3% in pre-market Thursday while Merck stock price is down 1%. Even though Merck and Seagen are currently in advanced talks, there are no guarantees the two companies will close a deal, t ...
Mode seleksi ketat (strict search) ON. Klik di sini untuk melihat lebih banyak artikel.
  Artikel 1 sampai 10